Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

A lawsuit against 23andMe is stirring a debate about what the proper role of government is in regulating how private ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

旧金山 - 目前市值为1.4927亿美元的基因检测公司23andMe Holding Co. (OTC: MEHCQ)周五宣布，已与公司联合创始人Anne Wojcicki领导的非营利组织TTAM Research Institute达成最终协议，以3.05亿美元出售其绝大部分资产。根据 InvestingPro 数据显示，该公司在过去十二个月面临重大财务挑战，EBITDA为-1.6489亿美元。

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...